September 1st 2025
The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.
Adding Icosapent Ethyl to Statin Therapy Cuts Stroke Risk, Analysis of REDUCE-IT Trial Finds
March 17th 2021International Stroke Conference 2021: A new analysis of the landmark REDUCE-IT trial found that adding icosapent ethyl to treatment regimens that already include statins further reduces stroke risk.